Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968169 | 0.98 | ABCC4 (0.45) | ABCC4MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL28157601 | 0.98 | ABCC4 (0.45) | ABCC4MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL6120452 | 0.98 | ABCC4 (0.45) | ABCC4MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL12614147 | 0.94 | MAPT (0.52) | ABCC4MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL5745232 | 0.78 | HIF1A (0.43) | MAPTTSHRACLY | |
| SCHEMBL5950908 | 0.78 | MAPT (0.48) | ABCC4MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL4013371 | 0.78 | MAPT (0.48) | ABCC4MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL4539892 | 0.77 | ABCC4 (0.39) | ABCC4MAPTALDH1A1LMNAL3MBTL1 | |
| Zinc Ion SCHEMBL6120455 | 0.77 | ABCC4 (0.39) | ABCC4MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL5998393 | 0.76 | MAPT (0.42) | ABCC4MAPTALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296702-B2 | Rosuvastatin enantiomer compounds | SCALLEN, MICHAEL | 2016-03-29 | — | — | US | claimed |
| WO-2012063115-A2 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM VIA NOVEL AMINE INTERMEDIATE | JUBILANT LIFE SCIENCES LTD. (IN) | 2012-05-18 | — | — | WO | claimed |
| WO-2010030201-A2 | STABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING A PHARMACEUTICALLY ACCEPTABLE SALT OF [(E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2- [METHYL(METHYLSULFONYL)AMINO]PYRIMIDINE-5-YL] (3R, 5S) - 3,5 DIHYDROXYHEPT-6- ENOIC ACID | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2010-03-18 | — | — | WO | claimed |
| EP-1223918-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A HMG COA REDUCTASE INHIBITOR | AstraZeneca AB (SE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001054668-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A HMG REDUCTASE INHIBITOR | ASTRAZENECA AB (SE) | 2001-08-02 | — | — | WO | claimed |
| EP-0300249-B1 | 7-[1H-pyrrol-3-yl]-substituted 3,5-dihydroxy-heptane acids, their corresponding delta-lactones and salts, processes for their manufacture, their use as medicines, pharmaceutical preparations and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-02-03 | — | — | EP | claimed |
| EP-0300249-A1 | 7-[1H-pyrrol-3-yl]-substituted 3,5-dihydroxy-heptane acids, their corresponding delta-lactones and salts, processes for their manufacture, their use as medicines, pharmaceutical preparations and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-01-25 | — | — | EP | claimed |
| JP-10067744-A | — | — | None | — | — | JP | disclosed |
| WO-2025090648-A1 | METHODS AND COMPOSITIONS FOR INHIBITING METASTASIS OF SOLID TUMORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-118772052-A | Medical intermediate and preparation method thereof | 湖南九维生物医药有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3833335-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITORS AND FENOFIBRATE | Intas Pharmaceuticals Ltd. (IN) | 2021-06-16 | — | — | EP | disclosed |
| WO-2021019493-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITORS AND FENOFIBRATE | INTAS PHARMACEUTICALS LTD. (IN) | 2021-02-04 | — | — | WO | disclosed |
| JP-H1067744-A | 6-(HYDROXYMETHYL-ETHYL) PYRIDINE | BAYER AG | 1998-03-10 | — | — | JP | disclosed |
| EP-0617000-A2 | 4-Fluorobiphenyl derivatives | FUJIREBIO Inc. (JP) | 1994-09-28 | — | — | EP | disclosed |
| EP-0361273-B1 | 7-Substituted derivatives of 3,5-dihydroxyhept-6-inoic acid, process for their preparation, their use as medicaments, and intermediates | HOECHST AG (DE) | 1994-03-23 | — | — | EP | disclosed |
| EP-0300249-B1 | 7-[1H-pyrrol-3-yl]-substituted 3,5-dihydroxy-heptane acids, their corresponding delta-lactones and salts, processes for their manufacture, their use as medicines, pharmaceutical preparations and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-02-03 | — | — | EP | disclosed |
| US-5055484-A | Anticholesterol and antilipemic agent | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-10-08 | — | — | US | disclosed |
| EP-0361273-A2 | 7-Substituted derivatives of 3,5-dihydroxyhept-6-inoic acid, process for their preparation, their use as medicaments, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-04-04 | — | — | EP | disclosed |
| EP-0244364-A2 | Preparation of olefinic compounds | SANDOZ AG (CH) | 1987-11-04 | — | — | EP | disclosed |